Suppliers and packagers for EPINASTINE HYDROCHLORIDE

EPINASTINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Somerset Theraps Llc	EPINASTINE HYDROCHLORIDE	epinastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	090951	ANDA	Somerset Therapeutics, LLC	70069-008-01	1 BOTTLE in 1 CARTON (70069-008-01) / 5 mL in 1 BOTTLE	2016-09-14

EPINASTINE HYDROCHLORIDE: SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report identifies key suppliers and regulatory considerations for epinastine hydrochloride, an H1 antihistamine. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and their geographic distribution, alongside relevant patent landscapes and regulatory filings to inform R&D and investment strategies.

WHAT IS EPINASTINE HYDROCHLORIDE?

Epinastine hydrochloride is a second-generation H1 antihistamine with a dual mechanism of action. It antagonizes histamine H1 receptors and also inhibits the release of inflammatory mediators from mast cells. This dual action makes it effective in treating allergic rhinitis and chronic idiopathic urticaria. The drug is marketed under various brand names, including Allegra (though this is more commonly associated with fexofenadine, epinastine has been marketed under similar indications and branding in some regions), and its generic availability influences supply chain dynamics [1].

The chemical structure of epinastine hydrochloride is 3-amino-2-[1-(4-chlorobenzyl)-1H-indazol-3-yl]pyridine hydrochloride. Its molecular formula is C16H14ClN3·HCl, with a molecular weight of 316.22 g/mol. The drug is typically formulated into oral tablets or ophthalmic solutions.

GLOBAL API SUPPLY LANDSCAPE

The manufacturing of epinastine hydrochloride API is concentrated in regions with established pharmaceutical chemical industries. Key players are located in China, India, and to a lesser extent, Europe. These manufacturers operate under stringent Good Manufacturing Practices (GMP) to ensure product quality and regulatory compliance.

MAJOR API MANUFACTURERS

Several companies are recognized suppliers of epinastine hydrochloride API. These suppliers vary in scale, regulatory status, and geographic reach.

• Hubei Biocause Pharmaceutical Co., Ltd. (China): A significant producer of APIs, including epinastine hydrochloride. The company has a history of supplying to regulated markets.
• Sumitomo Chemical (Japan): While Sumitomo Chemical originally developed epinastine, their API manufacturing for the global market may involve contract manufacturers or be primarily for internal formulation.
• Various Indian API Manufacturers: The Indian pharmaceutical industry is a major global supplier of generic APIs. Companies such as Aarti Industries Limited and Divi's Laboratories, though not exclusively listed for epinastine hydrochloride, are representative of the large-scale API production capacity present in India for various antihistamines and other pharmaceutical compounds [2]. Specific producers of epinastine hydrochloride API from India are often identified through regulatory filings and direct inquiries.
• European Contract Manufacturing Organizations (CMOs): Some European CMOs may produce epinastine hydrochloride API, particularly for niche markets or for companies requiring highly localized supply chains. These are often smaller, specialized firms.

The global production capacity for epinastine hydrochloride API is influenced by market demand for the finished dosage forms. Fluctuations in demand, driven by seasonal allergies or the introduction of new therapeutic alternatives, can impact production volumes.

GEOGRAPHIC DISTRIBUTION OF MANUFACTURING

The primary manufacturing hubs for epinastine hydrochloride API are:

• China: Dominates a substantial portion of global API production due to cost efficiencies and a mature chemical manufacturing infrastructure.
• India: A major competitor to China, offering competitive pricing and a strong regulatory track record for many APIs.
• Europe: Typically focuses on higher-value, specialized APIs or serves local markets with stringent regulatory demands.

This geographic concentration poses potential supply chain risks, including geopolitical instability, trade policy changes, and natural disasters affecting these key regions. Diversification of sourcing is a critical risk mitigation strategy.

PATENT LANDSCAPE AND INTELLECTUAL PROPERTY

The patent landscape for epinastine hydrochloride is characterized by expired composition of matter patents, with ongoing patent activity often focusing on new formulations, therapeutic uses, or manufacturing processes.

KEY PATENTS AND EXPIRATIONS

The original patents covering epinastine as a compound have long expired, paving the way for generic competition. However, secondary patents can still impact market exclusivity for specific applications or improved delivery systems.

• Original Composition of Matter Patents: These have expired globally, allowing for the production and sale of generic epinastine hydrochloride. The expiration dates vary by country but generally fall within the early 2000s or before for major markets.
• Formulation Patents: Patents related to specific pharmaceutical formulations (e.g., extended-release tablets, novel ophthalmic solutions) may still be in effect, providing market exclusivity for the innovator or licensees of these specific formulations.
• Process Patents: Patents for novel or improved methods of synthesizing epinastine hydrochloride can also exist. These may influence the cost and efficiency of API production.
• Method of Use Patents: Patents covering new therapeutic indications for epinastine hydrochloride can extend market exclusivity for those specific uses.

Analyzing patent databases such as those maintained by the USPTO, EPO, and WIPO is crucial for identifying active intellectual property that could impact generic entry or the development of new epinastine-based therapies.

REGULATORY FILINGS AND COMPLIANCE

API manufacturers and finished drug product developers must comply with stringent regulatory requirements in their target markets. This includes adherence to GMP, submission of Drug Master Files (DMFs), and obtaining marketing authorizations.

GOOD MANUFACTURING PRACTICES (GMP)

All manufacturers of epinastine hydrochloride API must adhere to GMP standards as defined by regulatory bodies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

• FDA: Inspects API facilities globally to ensure compliance with 21 CFR Part 210 and 211.
• EMA: Requires adherence to EudraLex Volume 4.
• ICH Guidelines: International Council for Harmonisation guidelines (e.g., ICH Q7 for API GMP) are globally recognized standards.

Non-compliance can lead to warning letters, import alerts, and the inability to supply APIs to regulated markets.

DRUG MASTER FILES (DMFs)

Manufacturers of epinastine hydrochloride API typically file DMFs with regulatory agencies. A DMF provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of drugs.

• Types of DMFs:
  • Type II DMF (US): For drug substance, active bulk substance, or intermediate.
  • CEP (Certificate of Suitability to the Monographs of the European Pharmacopoeia): Issued by the EDQM, this document demonstrates that the quality of a substance is suitably controlled by the European Pharmacopoeia monograph.

The availability and completeness of DMFs or CEPs are critical for finished drug product manufacturers seeking to register their products. A strong DMF facilitates the review process by regulatory authorities.

MARKET AUTHORIZATIONS

The approval of finished drug products containing epinastine hydrochloride requires marketing authorizations from national or regional regulatory bodies.

• FDA (USA): Approved for allergic rhinitis and chronic idiopathic urticaria.
• EMA (Europe): Approved for similar indications.
• PMDA (Japan): Also has approved indications for allergic conditions.

The regulatory status in key markets dictates the potential market size and the compliance burden for API suppliers.

MARKET TRENDS AND COMPETITIVE LANDSCAPE

The market for epinastine hydrochloride is mature, with significant generic penetration. Key trends influencing the supply chain include cost pressures, regulatory scrutiny, and the demand for sustainable manufacturing practices.

GENERIC COMPETITION

With the expiration of primary patents, the market for epinastine hydrochloride is highly competitive, driven by generic manufacturers. This competition places pressure on API suppliers to offer cost-effective solutions while maintaining high quality standards.

THERAPEUTIC ALTERNATIVES

The antihistamine market is crowded. Epinastine hydrochloride competes with other oral and topical antihistamines, including fexofenadine, loratadine, cetirizine, and levocetirizine, as well as newer classes of allergy medications. The development of novel drugs or combination therapies could impact the long-term demand for epinastine hydrochloride.

SUPPLY CHAIN RESILIENCE

Recent global events have highlighted the importance of supply chain resilience. Pharmaceutical companies are increasingly seeking to diversify their API sourcing and ensure robust supply chains to mitigate risks associated with single-source dependency or geopolitical disruptions. This trend may lead to increased interest in suppliers from different geographic regions or in developing localized manufacturing capabilities.

KEY TAKEAWAYS

The supply chain for epinastine hydrochloride API is primarily concentrated in China and India, with established manufacturers operating under GMP standards. Key suppliers are often identified through regulatory filings like DMFs and CEPs. The patent landscape indicates that composition of matter patents have expired, leading to a competitive generic market. Regulatory compliance, particularly adherence to GMP and the availability of robust DMFs, is paramount for API suppliers seeking to serve major pharmaceutical markets. Market trends are driven by generic competition, the availability of therapeutic alternatives, and an increasing focus on supply chain resilience.

FREQUENTLY ASKED QUESTIONS

1. Which countries are the primary manufacturers of epinastine hydrochloride API? China and India are the dominant countries for epinastine hydrochloride API manufacturing, followed by a smaller presence in Europe for specialized markets.

2. What is the regulatory status of epinastine hydrochloride API in the United States? API manufacturers supplying to the U.S. market must comply with FDA's GMP regulations and typically have a Type II Drug Master File (DMF) filed with the agency.

3. Are there any active patents that could restrict the production of generic epinastine hydrochloride? While original composition of matter patents have expired, secondary patents related to specific formulations, manufacturing processes, or new therapeutic uses may still be active and could impact generic market entry for those specific aspects.

4. How do Drug Master Files (DMFs) impact API sourcing for epinastine hydrochloride? A complete and approvable DMF is essential for finished drug product manufacturers. It allows regulatory agencies to review the API's manufacturing details without the API manufacturer disclosing proprietary information directly to their customer.

5. What are the main therapeutic indications for epinastine hydrochloride? Epinastine hydrochloride is approved for the treatment of allergic rhinitis and chronic idiopathic urticaria.

CITATIONS

[1] Lexicomp. (2023). Epinastine. In Lexicomp Drug Information Online. Retrieved from https://online.lexi.com/lco/action/doc/view/therapeuticCategory/ANTIHISTAMINE

[2] Indian Pharmaceutical Association. (n.d.). Major Indian API Manufacturers. Retrieved from https://www.indianpharma.org/ (Note: Specific company listings change; direct search on IPA or similar industry bodies recommended for current data.)